Sydney Stewart, Author at BioTuesdays

Markets

HCW ups Aravive PT to $26 from $15

H.C. Wainwright raised its price target for Aravive (NASDAQ:ARAV) to $26 from $15 after the company announced successful completion of its Phase 1b trial testing AVB-500 in patients with platinum resistant ovarian...

July 23, 2020

Markets

Brookline starts MiRagen Therapeutics at buy; PT $6

Brookline Capital Markets initiated coverage of MiRagen Therapeutics (NASDAQ:MGEN) with a “buy” rating and 12-to-18 month price target of $6. The stock closed at $1.02 on July 20. MiRagen is working in hematologic...

July 21, 2020

Markets

Piper Sandler starts Zynex at OW; PT $30

Piper Sandler launched coverage of Zynex (NASDAQ:ZYXI) with an “overweight” rating and $30 price target. The stock closed at $21.42 on July 17. Zynex sells the only three-in-one, at home, chronic pain management product...

July 20, 2020

Developments

Liminal BioSciences acquires Fairhaven Pharmaceuticals

Liminal BioSciences (NASDAQ, TSX:LMNL) acquired closely-held Fairhaven Pharmaceuticals for $8-million (Canadian) in common shares. Fairhaven’s assets include a preclinical research program of small molecule...

July 17, 2020

Markets

SVB Leerink cuts Benefytt Technologies to MP; PT up to $31 from $27.50

SVB Leerink downgraded Benefytt Technologies (NASDAQ:BFYT) to “market perform” from “outperform” but raised its price target to $31 from $27.50 after Madison Dearborn Partners agreed to acquire Benefytt for $31 a share...

July 14, 2020

Executive Moves

Elemer Piros rejoins Roth healthcare research team

Elemer Piros Elemer Piros has rejoined the healthcare research team at Roth Capital Partners as managing director, senior research analyst covering biotechnology. His research coverage is expected to include small...

July 9, 2020

Markets

AGP starts Organigram at buy; PT $4

Alliance Global Partners initiated coverage of Organigram Holdings (TSX:OGI) with a “buy” rating and price target of $4 (Canadian). The stock closed at $2.11 on July 6. “We view Organigram’s low-cost indoor [cannabis]...

July 7, 2020

Developments

IntelGenx in feasibility pact with Cybin for fast-acting, orally-dissolving psilocybin film

IntelGenx (TSXV:IGX; OTCQB:IGXT) inked a feasibility agreement with Cybin for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin. Cybin is Canada’s premier mushroom...

July 7, 2020

Developments

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Liminal BioSciences (NASDAQ, TSX:LMNL) provided a guidance update on the timing of certain expected key milestones for 2020. The company withdrew guidance in May because of the COVID-19 pandemic. In a statement, Kenneth...

July 1, 2020

Markets

CohBar added to Russell 2000 index; raises $4.4-million in ATM offering

CohBar (NASDAQ:CWBR) was added to the small-cap Russell 2000 index during its latest reconstitution. The company also sold common stock through its existing at-the-market (ATM) offering, with net proceeds of about $4.4...

June 30, 2020

Author - Sydney Stewart

HCW ups Aravive PT to $26 from $15

Brookline starts MiRagen Therapeutics at buy; PT $6

Piper Sandler starts Zynex at OW; PT $30

Liminal BioSciences acquires Fairhaven Pharmaceuticals

SVB Leerink cuts Benefytt Technologies to MP; PT up to $31 from $27.50

Elemer Piros rejoins Roth healthcare research team

AGP starts Organigram at buy; PT $4

IntelGenx in feasibility pact with Cybin for fast-acting, orally-dissolving psilocybin film

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

CohBar added to Russell 2000 index; raises $4.4-million in ATM offering

Subscribe